General

ABL DIAGNOSTICS (ABLD) has announced the signing of a liquidity contract with ALLInvest Securities, effective from the morning of 24.04.2024. ABL Diagnostics SA (EPA:ABLD)WOIPPY, FRANCE, April 24, 2024 /EINPresswire.com/ — ABL DIAGNOSTICS (ticker ABLD, ISIN FR001400AHX6), Euronext Compartment B, announces that it has signed a liquidity contract with ALLInvest Securities, effective from the morning of

Newburyport (MA, USA) – AdvancedDx Biological Laboratories USA Inc., an affiliate of ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories, is pleased to announce today the execution of a non-exclusive distribution agreement to confer to Medline Industries, LP (www.medline.com) the rights to promote and

Newburyport (MA, USA) – AdvancedDx Biological Laboratories USA Inc., an affiliate of ABL Diagnostics S.A. (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories is pleased to announce today the execution of a new agreement with VELA Diagnostics USA Inc. to expand the scope of services announced

Woippy (France) – ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories is announcing today the execution of a distribution agreement conferring to PALEX (https://www.palexmedical.com/) the rights to offer ABL Diagnostics products to laboratories in Spain. The collaboration will be carried out through a

Woippy, le 4 mars 2024 à 8h ABL Diagnostics (FR001400AHX6) (“ABLD” or the “Company”) announced today that a total of three block transactions since August 2023 for a total of 59,651 shares of its common stock have been reported to ONDE, the central information filing system of the Autorité des Marchés Financiers (AMF) and are

Newburyport (MA, USA) – AdvancedDx Biological Laboratories USA Inc., the US affiliate of ABL Diagnostics (FR001400AHX6 – ABLD), a Euronext-listed French company, is pleased to announce the availability in the USA, of an assay enabling HIV whole genome genotyping by sequencing. DeepChek® Assay Whole Genome HIV-1 Genotyping has been developed for use with the leading next

Woippy (France) – ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories is pleased to announce today the execution of an exclusive distribution agreement to confer to AB ANALITICA (https://www.abANALITICA.com/en/) the rights to promote and commercialize ABLD assays and software systems to all laboratories

Newburyport (MA, USA) – AdvancedDx Biological Laboratories USA Inc., an affiliate of ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories is pleased to announce today the opening of its new temperature-controlled warehouse in the USA, to offer its clients and partners improved quality and

INTRODUCING THE DEEPCHEK GENOTYPING TECHNOLOGY OVERVIEW & USERS EXPERIENCE Webinar from Tuesday January 30, 2024 – 4pm CET Revue de la Solution DeepChek Genotyping à travers un Webinaire présenté par notre équipe et par un panel d’experts :

REVUE DE LA TECHNOLOGIE DE GENOTYPAGE DEEPCHEK PRESENTATION & EXPERIENCES UTILISATEUR Webinaire réalisé le mardi 23 janvier 2024 – 10h00 CET Revue de la Solution DeepChek Genotyping à travers un Webinaire présenté par notre équipe et par un panel d’experts :